



Clinical and Translational Updates in Renal Cell Carcinoma

Guest Editor:

Dr. Irbaz Bin Riaz

1. Dana Farber Cancer Institute,
Harvard Medical School, Boston,
MA, USA
2. Mayo Clinic Arizona, Alix
School of Medicine, Rochester,
MN, USA

Deadline for manuscript
submissions:

2 July 2024

Message from the Guest Editor

Dear Colleagues,

This special issue aims to highlight the latest clinical and translational developments in renal cell carcinoma. We welcome original manuscripts (preferred) and high-quality reviews covering updates on both early and advanced renal cell carcinoma.

We welcome manuscripts covering various aspects, including developments related to basic and translational science, molecular and computational biology, artificial intelligence, and machine learning, as well as the clinical management of nuanced issues in the perioperative/adjvant and metastatic setting.

If you have an interesting proposal related to renal cell carcinoma that is not covered by the categories listed above, please feel free to submit your proposal for consideration. We look forward to receiving your high-quality contributions.

Dr. Irbaz Bin Riaz
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI